FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
29/01/2026
Voltar para busca
Dado oficial do USPTO
UMZOON
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 44
Data de depósito
06/02/2024
Data de registro
17/06/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/06/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
CH
Examinador
DUBIN, DAVID I
Unidade examinadora
L70
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Novartis AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of dermatological diseases; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in the treatment of hematology diseases; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in the treatment of ophthalmology diseases; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Classe 44
Collection and preservation of human blood; Collection and preservation services for tissue and cells, namely, collection and banking of umbilical cord tissue perivascular stem cells; medical diagnostic services; medical treatment services being medical analysis services relating to the treatment of patients; provision of medical information and remote monitoring of medical data for medical diagnosis and medical treatment
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/01/2026
FIMP
FINAL DISPOSITION PROCESSED
14/01/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/10/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
24/09/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
24/09/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/09/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/06/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
17/06/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/04/2025
PUBO
PUBLISHED FOR OPPOSITION
29/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/02/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/02/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/02/2025
RFNT
REFUSAL PROCESSED BY IB
17/01/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/01/2025
RFRR
REFUSAL PROCESSED BY MPU
02/01/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
17/12/2024
CNRT
NON-FINAL ACTION WRITTEN
16/12/2024
DOCK
ASSIGNED TO EXAMINER
09/08/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
13/05/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/05/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
13/05/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
13/05/2024
MAFR
APPLICATION FILING RECEIPT MAILED
10/05/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/05/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
25/04/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace UMZOON ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.